Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.76B |
| 2 |
Tesla
TSLA
|
+$1.37B |
| 3 |
Amazon
AMZN
|
+$623M |
| 4 |
AbbVie
ABBV
|
+$398M |
| 5 |
Qualcomm
QCOM
|
+$394M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$603M |
| 3 |
Micron Technology
MU
|
+$366M |
| 4 |
Meta Platforms (Facebook)
META
|
+$365M |
| 5 |
UnitedHealth
UNH
|
+$353M |
Sector Composition
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.91% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.47% |
| 5 | Industrials | 7.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3051
Vanguard Industrials ETF
VIS
$6.14B
| $323K | ﹤0.01% |
2,100
-500
| -19% | -$76.9K |
|
3052
Enlivex Therapeutics
ENLV
$24.8M
| $322K | ﹤0.01% |
38,390
+14,600
| +61% | +$122K |
|
3053
QuinStreet
QNST
$922M
| $322K | ﹤0.01% |
+21,000
| New | +$322K |
|
|
CYAN
3054
DELISTED
Cyanotech Corp
CYAN
| $322K | ﹤0.01% |
140,400
+2,300
| +2% | +$5.28K |
|
|
UFAB
3055
DELISTED
Unique Fabricating, Inc.
UFAB
| $321K | ﹤0.01% |
83,199
+23,000
| +38% | +$88.7K |
|
3056
PDS Biotechnology
PDSB
$55.5M
| $319K | ﹤0.01% |
120,269
+28,700
| +31% | +$76.1K |
|
|
BNSO
3057
DELISTED
Bonso Electronic International
BNSO
| $319K | ﹤0.01% |
138,900
+600
| +0.4% | +$1.38K |
|
|
OPRA
3058
Opera Ltd
OPRA
$1.76B
| $318K | ﹤0.01% |
34,423
-2,877
| -8% | -$26.6K |
|
|
FSTX
3059
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $317K | ﹤0.01% |
50,233
+12,783
| +34% | +$80.7K |
|
3060
Business First Bancshares
BFST
$734M
| $314K | ﹤0.01% |
12,606
+4,402
| +54% | +$110K |
|
3061
Highway Holdings
HIHO
$8.15M
| $314K | ﹤0.01% |
193,627
+6,000
| +3% | +$9.73K |
|
|
MNTX
3062
DELISTED
Manitex International, Inc.
MNTX
| $314K | ﹤0.01% |
52,699
+14,659
| +39% | +$87.3K |
|
3063
Corporacion America
CAAP
$3.23B
| $313K | ﹤0.01% |
+52,100
| New | +$313K |
|
3064
Arcosa
ACA
$4.76B
| $312K | ﹤0.01% |
7,000
-1,200
| -15% | -$53.5K |
|
|
OSN
3065
DELISTED
Ossen Innovation Co., Ltd.
OSN
| $312K | ﹤0.01% |
101,207
+59,401
| +142% | +$183K |
|
|
SORL
3066
DELISTED
SORL Auto Parts, Inc.
SORL
| $307K | ﹤0.01% |
+69,087
| New | +$307K |
|
|
PLXP
3067
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $306K | ﹤0.01% |
70,111
+1,400
| +2% | +$6.11K |
|
3068
Summit Therapeutics
SMMT
$13.3B
| $304K | ﹤0.01% |
189,834
+77,728
| +69% | +$124K |
|
|
AKTX
3069
Akari Therapeutics
AKTX
$25.3M
| $301K | ﹤0.01% |
8,597
+1,815
| +27% | +$63.5K |
|
3070
First Trust Exchange-Traded Fund VI Multi-Asset Diversified Income Index Fund
MDIV
$434M
| $301K | ﹤0.01% |
+16,000
| New | +$301K |
|
3071
Ternium
TX
$6.73B
| $301K | ﹤0.01% |
13,700
-237,800
| -95% | -$5.22M |
|
3072
Futu Holdings
FUTU
$25.9B
| $298K | ﹤0.01% |
+28,896
| New | +$298K |
|
|
EVOP
3073
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $298K | ﹤0.01% |
11,300
-11,200
| -50% | -$295K |
|
3074
Greenlight Captial
GLRE
$431M
| $295K | ﹤0.01% |
29,200
+9,814
| +51% | +$99.1K |
|
3075
Theriva Biologics
TOVX
$3.91M
| $295K | ﹤0.01% |
2,327
+321
| +16% | +$40.7K |
|